World ADC San Diego 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences

ADC translational medicine at World ADC San Diego 2026

Oct 12–15, 2026 San Diego, CA ~1.3k attendees Website

24 organizations at World ADC San Diego 2026 present work in translational medicine: 16 drug developers and 8 technology and service providers. Between them they bring 58 presentations to the program. Most represented: Merck & Co. (6 on the program), Daiichi Sankyo (5 on the program), Iksuda Therapeutics (3 on the program). 21 of them have their own page in this guide. As of Oct 8, 2026.

All 165 organizations at World ADC San Diego 2026 →

Showing 1–9 of 24 organizations

Organization	World ADC San Diego 2026 Attendance
Merck & Co. Rahway, NJ
merck.com Large pharma Global pharmaceutical company, known as MSD outside the US and Canada, with marketed cancer medicines and an ADC pipeline.	Panel Mon Oct 12 12:00pm Breaking Down Strategic Approaches to Ensure Product Quality in Late-Stage ADC Manufacturing Pre-conference: 8th CMC Day Talk Wed Oct 14 11:00am Harnessing Computational & Mechanistic Insights Into Chemoselective Reduction for Engineered Cysteine Site-Specific ADCs Discovery Chemistry Talk Wed Oct 14 12:00pm Assessing Case Study Characterization & Control of an ADC Variant to Mitigate Analytical Comparability Risk Process & Analytical Development Talk Wed Oct 14 2:00pm Mechanistic QSP Platform for ADCs in Oncology: Exploring Prospective Efficacy & Safety Predictions to Guide Study Design Translational Medicine Talk Wed Oct 14 3:00pm Evaluating Environmental Temperature as a Hidden Critical Factor in icIEF for a Late-Stage ADC Process & Analytical Development
Daiichi Sankyo Tokyo, Japan
daiichisankyo.com Large pharma Japanese pharmaceutical company behind the DXd ADC platform, including trastuzumab deruxtecan and datopotamab deruxtecan.	Panel Mon Oct 12 2:30pm Tackling Opportunities & Strategies to Identify High Risk Patients & Best Mitigate Clinical ADC Toxicities VIRTUAL PRESENTATION Pre-conference: 7th Toxicity Day Panel Tue Oct 13 8:00am Contextualizing the Current Status of Novel ADC Design & Development to Ensure Future ADC Success & Differentiated Patient Impact Plenary · with Amgen, Iksuda Therapeutics, Pfizer +1 more ADC discovery chemistryADC discovery biology Talk Tue Oct 13 2:30pm The Transition of an ADC From Late-Line to First-Line Therapy in HER2+ Breast Cancer & Earlier Line Gastric Cancer: The Trastuzumab Deruxtecan (T-DXd) Example Clinical Lessons Panel Tue Oct 13 3:30pm Assessing the Growing Importance of ADC Sequencing & Combination Approaches to Optimize Differentiated Clinical Performance Clinical Lessons Talk Wed Oct 14 2:00pm Highlighting Preclinical Development of DS-3939a, a DXd-ADC Targeting TA-MUC1 Preclinical Workshop Thu Oct 15 1:00pm Breaking Down Clinical Characterization & Differentiation Strategies to Set Up ADC Development for Success in an Increasingly Busy Oncology Landscape Post-conference workshop for Translational Medicine & Clinical Lessons · with NEOK Bio
Iksuda Therapeutics Newcastle upon Tyne, UK
iksuda.com Biotech UK ADC developer with clinical programs and new payload classes, including a protein-alkylating payload.	Chair Tue Oct 13 7:55am Part of Striving for the Next Wave of ADC Innovation: Contextualizing Novel ADC Mechanism & Design Validation to De-Risk Future ADC Development & Deliver Differentiated Patient Benefit Chair’s Opening Remarks Plenary ADC discovery chemistryADC discovery biology Panel Tue Oct 13 8:00am Contextualizing the Current Status of Novel ADC Design & Development to Ensure Future ADC Success & Differentiated Patient Impact Plenary · with Amgen, Daiichi Sankyo, Pfizer +1 more ADC discovery chemistryADC discovery biology Talk Tue Oct 13 2:00pm Beyond TopoI & Tubulin: Advancing a First-in-Class Protein Alkylation Payload ADC IKS073 Preclinical Talk Tue Oct 13 3:00pm Spotlighting the Clinical Profile & Positioning of IKS014 to Contextualize ADC Sequencing Clinical Lessons Panel Tue Oct 13 3:30pm What’s the New Path to the Next Generation of ADCs? Discovery Biology · with Sygnature Discovery, AstraZeneca, Pfizer +1 more Chair Navigating New & Crowded ADC Clinical Indications to Achieve Differentiation & Maximize Benefit to Patients Clinical Lessons Panel Wed Oct 14 12:30pm Navigating & Maximizing ADC Clinical Development to Best Deliver Patient Impact in Crowded Oncology Indications Clinical Lessons Panel Wed Oct 14 3:00pm Exploring Opportunities to Achieve Differentiated Clinical Benefit in a Crowded ADC Landscape Clinical Lessons Chair Wed Oct 14 5:30pm Part of Delving Into ADC Performance in Crowded Clinical Indications With Approved ADC Therapies to Understand How Differences in Biconjugate Design & Clinical Strategy Correlates to Patient Impact Chair’s Closing Remarks Plenary Clinical development Workshop Thu Oct 15 9:00am Connecting ADC Design & Component Contribution to Clinical Safety & Efficacy: What Makes a Clinically Impactful ADC? Post-conference workshop for Translational Medicine & Clinical Lessons
Takeda Tokyo, Japan
takeda.com Large pharma Japanese pharmaceutical company with marketed medicines in oncology, rare diseases, gastroenterology and other areas.	Talk Tue Oct 13 2:00pm Breaking Down Case Study Learnings to Optimize Outsourced Bioconjugation & Minimize ADC Production Cost & Timelines Manufacturing & Supply Chain Talk Wed Oct 14 2:00pm Developing an On-Column Capping Approach to Reduce Charge Heterogeneity of THIOMAB ADCs Process & Analytical Development Talk Wed Oct 14 2:30pm Beyond Allometry: Assessing Translational PK/PD Modeling for Human Projection of a Nonlinear Immune Cell Directed ADC Translational Medicine
CanWell Pharma Woburn, MA
canwellpharma.com Biotech Develops dual- and multi-payload ADCs on its StarLinker platform, plus TLR7 immune-agonist programs for cancer.	Talk Wed Oct 14 11:00am Exploring the Preclinical Profile & IND Journey of Dual Payload ADC CAN016 for HER2 Refractory Patients Translational Medicine Talk Wed Oct 14 2:00pm Spotlighting Clinical Performance of CAN1012: A TLR7 Agonist for the Treatment of PD-1 Refractory Melanoma & Dedifferentiated Liposarcoma Clinical Lessons
Eisai Tokyo, Japan
eisai.com Large pharma Japanese pharmaceutical company in neurology and oncology, researching ADCs including STING-agonist payload conjugates.	Talk Tue Oct 13 2:00pm Integrating Genomics & Real-World Data to Predict Fam-Trastuzumab Deruxtecan Response in Metastatic Breast Cancer Across HER2 Subtypes Translational Medicine Talk Wed Oct 14 2:00pm Exploring Development of E7766-Based STING ADCs: Contextualizing Influence of Payload Linker Attachment Site & Cleavage Kinetics Discovery Chemistry
Bionavigen
bionavigen.com Consulting & other services Consultancy advising on discovery, preclinical, translational, regulatory and early clinical development of biologics, including ADCs, bispecifics and gene therapies.	Chair Predicting, Characterizing & Mitigating ADC Toxicities to Widen Therapeutic Index Pre-conference: 7th Toxicity Day Talk Mon Oct 12 10:00am Breaking Down Toxicity Considerations for Non-Cytotoxic Payloads & Alternative Antibody Formats to Unlock Differentiated ADC Therapeutic Index Pre-conference: 7th Toxicity Day Chair Optimizing ADC Patient Selection, Dosing & Trial Design to Set Up Early ADC Clinical Development for Success Translational Medicine Panel Tue Oct 13 3:00pm Evaluating the Need for Biomarker & Patient Selection Tools in an Increasingly Busy ADC Field Translational Medicine Talk Wed Oct 14 12:30pm Presentation & Fireside Chat: Beyond Antibody, Linker & Payload – Is Intracellular Delivery the Next Frontier for ADCs? Preclinical · with Defence Therapeutics, Genentech Workshop Thu Oct 15 9:00am Translating ADC Tolerability: Deep-Diving Into Toxicity Characterization & Preclinical Strategy to Better Predict ADC Clinical Safety Profiles Post-conference workshop for Preclinical & Translational Medicine
GB GG Biotech Consulting
	Chair Navigating New & Crowded ADC Clinical Indications to Achieve Differentiation & Maximize Benefit to Patients Clinical Lessons Chair Optimizing ADC Patient Selection, Dosing & Trial Design to Set Up Early ADC Clinical Development for Success Translational Medicine Panel Wed Oct 14 3:00pm Debating the Key Biomarker, Dosing & Development Strategies to Set Up Early ADC Clinical Development for Success Translational Medicine Workshop Thu Oct 15 1:00pm Balancing the Pace of Preclinical Development & Confident In Vivo Analysis to Optimize ADC Speed to Clinic Post-conference workshop for Preclinical & Translational Medicine · with Genmab
Kivu Bioscience San Mateo, CA
kivubioscience.com Biotech Develops ADCs with topoisomerase I inhibitor payloads, led by the PTK7-targeted KIVU-107 in a Phase 1 trial.	Talk Tue Oct 13 11:00am Optimizing ADC Design, Preclinical Evaluation & Clinical Trial Design for Clinical Development Success Translational Medicine Chair Tue Oct 13 6:45pm Part of Demonstrating the Transformative Impact of ADCs to Reshape the Standard of Oncology Care & Deliver Improved Therapeutic Outcomes for Patients in Metastatic & Early-Stage Settings Chair’s Closing Remarks Plenary Clinical development Chair Wed Oct 14 7:55am Part of Beyond the Topo1 Dogma: Unveiling Rationale-Driven Novel Payload Development & Properties to Herald ADCs with New Mechanisms & Improved Therapeutic Index Chair’s Opening Remarks Plenary ADC discovery chemistry